LONDON: British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States ...

Belgium's EsoBiotec has also been conducting clinical trials for CAR-T in patients with multiple myeloma in China since January, using a viral vector method.

The information is based on a press release statement. In other recent news, AstraZeneca has announced the completion of its acquisition of EsoBiotec, a biotech company specializing in cell therapies, ...

This acquisition introduces the innovative EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform to AstraZeneca’s portfolio, which could significantly enhance its cell therapy capabilities.

Earnings per share was 108.1 pence compared to 156.5 pence. Shares of drug firm AstraZeneca gained 1% after the company announced that it has successfully completed the acquisition of EsoBiotec.

Earnings per share was 108.1 pence compared to 156.5 pence. Shares of drug firm AstraZeneca are up 0.85% after the company announced that it has successfully completed the acquisition of EsoBiotec.

Drug firm AstraZeneca rose about 1 percent after successfully completing the acquisition of EsoBiotec. Close Brothers fell 2.8 percent after the loan book decreased 0.9 percent in the third ...

AstraZeneca announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity.

AstraZeneca announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...

AstraZeneca completes EsoBiotec acquisition for up to USD1 billion | Financial NewsThe Cambridge-based pharmaceuticals maker said the platform enables genetic instructions to be delivered directly ...

(Alliance News) - AstraZeneca PLC on Tuesday said it has completed its acquisition of Belgian biotechnology firm EsoBiotec SA, bolstering its cell therapy capabilities with a platform that could ...